Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: $DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.
GreenLab partners with Ginkgo Bioworks to scale up production of brazzein, a novel sweetener found in the fruit of the West African Oubli plant. This partnership aims to revolutionize the sweetener industry by leveraging GreenLab's technology to grow proteins in corn kernels and Ginkgo's capabilities to optimize production. By using Plant Trait Services, Protein Services, and Deployment Capabilities, GreenLab intends to be a leading supplier of brazzein to food and beverage companies, reducing market and technical risks.
Ginkgo Bioworks (NYSE: DNA) will be presenting at the ASGCT Annual Meeting, showcasing advancements in genetic medicines. The company will present posters on CAR signaling optimization and gene therapy design, highlighting their innovative platform. Ginkgo has grown its genetic medicine services and acquired Patch Biosciences to expand capabilities. The presentations demonstrate Ginkgo's commitment to driving innovation in genetic medicine development.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) will host a presentation and Q&A session to review business performance for the first quarter of 2024 on May 9, 2024. The event will begin at 5:30 p.m. ET and can be accessed via the company's investor relations website. Questions can be submitted in advance via social media or email.
